Castle Biosciences

Friendswood, Texas – October 15, 2026 -- Castle Biosciences (Nasdaq: CSTL) will release its financial results for the third quarter and nine months ended Sept. 30, 2026, after the close of market on Thursday, Nov. 5, 2026.

Management hosts webcast at 4:30 p.m. Eastern on Nov. 5

Company management will discuss the results on a live webcast at 4:30 p.m. Eastern time on the same day. A brief question-and-answer session will follow management's commentary.

Investors can access the webcast through the Investor Relations page of the company's website. The company asks participants to join at least 10 minutes before the start time. A replay will be available after the webcast concludes.

Friendswood – October 13, 2026 -- Management recommendations changed in line with TissueCypher risk classifications for 96% of patients in a multi-center Barrett's esophagus cohort, according to data Castle Biosciences (Nasdaq: CSTL) is presenting at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Oct. 9-14.

The company is presenting three studies: two case reports and one multi-center cohort study. All three examine whether the molecular test adds risk information beyond histopathology.

TissueCypher and clinicopathologic scoring agreed only slightly in the multi-center cohort

The cohort study (P5192) compared TissueCypher with the Progression in Barrett's (PIB) clinicopathologic approach and found only slight agreement (Cohen's κ = 0.04). TissueCypher classified 83% of patients as low risk and 17% as intermediate/high risk. The PIB score classified 31% as low risk and 69% as intermediate/high risk.

Stockholm – October 01, 2026 -- SciBase Holding AB has closed its rights issue fully subscribed, raising approximately SEK 57.5 million before issue costs to fund continued commercialisation of its Nevisense melanoma-diagnostics platform in the United States.

Shareholders cover nearly three-quarters of the offering

The subscription period, which ran through 29 September 2026, saw 2,681,085 shares subscribed with the support of subscription rights, equal to roughly SEK 40.2 million, or 69.9 percent of the issue. An additional 133,116 shares were subscribed without subscription rights, adding SEK 2.0 million, or 3.5 percent. In total, 2,814,201 shares were subscribed with and without rights, covering approximately SEK 42.2 million, or 73.4 percent of the SEK 57.5 million target.

Friendswood, Texas – September 28, 2026 -- Castle Biosciences, Inc. (Nasdaq: CSTL) said a new peer-reviewed study found its TissueCypher Barrett's Esophagus Test prompted clinicians to change management recommendations in 90% of cases involving patients with non-dysplastic Barrett's esophagus (NDBE).

The case series, published in Foregut: The Journal of the American Foregut Society, evaluated 30 NDBE patients tested as part of clinical care at Keck Medical Center of the University of Southern California (USC).

Test reclassifies risk within a population considered uniformly low-risk

TissueCypher classified 17% of the 30 patients as intermediate or high risk for progression to high-grade dysplasia or esophageal adenocarcinoma within five years, while 83% were confirmed low risk. All patients had received the same NDBE diagnosis prior to testing.

Stockholm – September 12, 2026 -- SciBase Holding AB (STO: SCIB) has received an additional order worth roughly $0.6 million, or approximately SEK 5 million, from Castle Biosciences (NASDAQ: CSTL) to accelerate an ongoing clinical study and prepare a second trial under their dermatology collaboration.

Order covers Nevisense Go devices and electrodes for atopic dermatitis research

The order includes both SciBase's portable Nevisense Go pen device and associated electrodes. Deliveries are scheduled to begin in the fourth quarter of 2026.

Collaboration targets relapse prediction in atopic dermatitis patients

SciBase and Castle Biosciences entered a collaboration and license agreement in 2025. The first joint study under that agreement aims to predict relapses in atopic dermatitis and is currently underway, with the new order funding both faster progression of that trial and groundwork for a follow-up study.